WeTrials
Recruiting

Phase II Trial of Palbociclib and Pembrolizumab in Central Nervous System Metastases

What is this study?

This study is testing two different medication combinations to see how well they treat cancer that has spread to the brain or spinal cord and has come back or continued to grow. Researchers want to find safer and more effective treatment options for patients facing this difficult diagnosis.

Who can participate?

You might be able to join if you have a solid tumor like breast cancer or melanoma that has spread to the brain or spinal cord, and the tumor is at least 10 millimeters in size. There are some rules about past treatments, so your care team will need to check your medical history first.

What will happen?

Depending on which group you join, you will receive either a targeted cancer drug called palbociclib alone or a combination of palbociclib and an immunotherapy drug called pembrolizumab. Your health and the response of the tumor will be closely monitored through regular check-ups and scans.

Where and when?

This study is currently recruiting patients and takes place in Boston, Massachusetts. Ask your doctor if this location works for you and if you might be a good fit.

Key Points
  • 1Tests treatments for cancer that has spread to the brain or spinal cord
  • 2Uses a combination of targeted therapy and immunotherapy
  • 3Currently recruiting patients in Boston, Massachusetts

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Metastatic Malignant Neoplasm to BrainRecurrent Brain MetastasesProgressive Brain Metastases

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.